Alireza Mansouri: Curasight Launches Phase 1 uTREAT Trial for Glioblastoma
Alireza Mansouri, Associate Professor at Penn State Health, shared a post on X:
“Exciting news on the horizon for glioblastoma fighters!
Danish company Curasight is gearing up to launch a Phase 1 trial for uTREAT, their targeted radiopharmaceutical, likely starting in Europe Q4 2025.
Full details pending EMA green light.
uPAR is a protein that’s overproduced in about 94% of high-grade gliomas like GBM, making tumors more aggressive and invasive.
Theranostics? It’s like a smart combo: Use imaging (uTRACE) to spot the cancer, then zap it precisely with therapy (uTREAT).
Why better than standard radiation?
This delivers radiation right inside the tumor cells, sparing healthy brain tissue and potentially cutting side effects.
Phase 1 trials are the first step in humans—focusing on safety, right dose, and early signs it works. uTREAT aims to prove it’s safe for newly diagnosed GBM patients post-surgery.
Stay tuned!”
More from Alireza Mansouri on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023